<DOC>
	<DOCNO>NCT00528268</DOCNO>
	<brief_summary>In single-center trial , evaluate effect NaPB presymptomatic Spinal Muscular Atrophy ( SMA ) type I ( cohort 1 ) presymptomatic SMA type II ( cohort 2 ) infant . A variety outcome measure perform study visit follow course disease . Total duration study type I infants 18 month , type II infant , 24 month .</brief_summary>
	<brief_title>Study Evaluate Sodium Phenylbutyrate Pre-symptomatic Infants With Spinal Muscular Atrophy</brief_title>
	<detailed_description>Perform phase I/II study evaluate effect Phenyl Butyrate ( PBA ) cohort 12 presymptomatic infant . These infant predict either SMA 1 2 give genotype family history old sibling respective SMA type . Our goal twofold : 1 ) collect additional safety pharmacokinetic data neonate young infant administer compound , within dose guideline already use urea cycle disorder therapy , 2 ) determine possible benefit early treatment intervention regard status denervation functional motor status specific time point match natural history data perform comparison . Data obtain aim guide future trial design determine efficacy PBA butyrate analog attenuate disease progression SMA subject identify presymptomatic period .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy , Spinal</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<mesh_term>4-phenylbutyric acid</mesh_term>
	<criteria>Laboratory documentation homozygous absence SMN1 exon 7 . Confirmation 3 SMN2 copy cohort 1 ; 4 copy cohort 2 . Family history affect sibling SMA type I cohort 1 SMA type II cohort 2 . Age ≤ 3 month , cohort 1 ; Age ≤ 6 month , cohort 2 . Written inform consent parents/guardian . Laboratory result demonstrate normal value age . Evidence hepatic insufficiency , renal insufficiency , edema sodium retention , know seizure disorder , urea cycle disorder , cardiac arrhythmia , congenital heart defect , hypertension , significant central nervous system ( CNS ) impairment , neurodegenerative neuromuscular disease SMA . History allergy/sensitivity sodium phenylbutyrate ( NaPB ) . Use NaPB within 30 day study entry . Serious illness require hospitalization ≤ 14 day prior study entry . Use medication intend treatment SMA include riluzole , valproic acid , hydroxyurea , oral use albuterol , NaPB , butyrate derivative , creatine , growth hormone , anabolic steroid , probenecid , oral parenteral use corticosteroid entry , agent anticipated increase decrease muscle strength agent presume histone deacetylase ( HDAC ) inhibition within 30 day prior study entry . Unwillingness travel study assessment .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Months</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Spinal Muscular Atrophy</keyword>
	<keyword>SMA</keyword>
	<keyword>Sodium Phenylbutyrate</keyword>
</DOC>